Pfizer EPS (Basic) decreased by 24.2% to $0.47 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 9.6%, from $0.52 to $0.47. Over 2 years (FY 2021 to FY 2024), EPS (Basic) shows a downward trend with a -39.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates improved profitability or a reduction in share count, while a decrease suggests declining earnings or equity dilution.
Basic earnings per share represents the portion of a company's profit allocated to each outstanding share of common stoc...
Investors compare this across large-cap technology peers to assess the efficiency of earnings generation relative to the equity base.
eps_basic| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.99 | $1.45 | $0.61 | $1.40 | $1.77 | $1.54 | $0.88 | $0.98 | $0.41 | -$0.42 | $0.55 | $0.01 | $0.79 | $0.07 | $0.52 | $0.51 | $0.62 | $0.47 |
| QoQ Change | — | +46.5% | -57.9% | +129.5% | +26.4% | -13.0% | -42.9% | +11.4% | -58.2% | -202.4% | +231.0% | -98.2% | >999% | -91.1% | +642.9% | -1.9% | +21.6% | -24.2% |
| YoY Change | — | — | — | — | +78.8% | +6.2% | +44.3% | -30.0% | -76.8% | -127.3% | -43.9% | -97.6% | +288.1% | — | -5.5% | >999% | -21.5% | -9.6% |